DSGN Design Therapeutics, Inc.

Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.

$17.78  -0.97 (-5.17%)
As of 11/26/2021 13:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/26/2021
Outstanding shares:  55,662,501
Average volume:  148,891
Market cap:   $1,043,671,894
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    25056L103
ISIN:        US25056L1035
Sedol:      BMFK3H6
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.51
PS ratio:   0.00
Return on equity:   -7.23%
Net income %:   -85,827.27%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy